From cardiovascular adverse events to complex dosing regimens, oncology trials present unique safety-related considerations. Left unaddressed, they could undermine a trial or put patient safety at risk. In this paper, we discuss some of those issues and how sponsors can best address them.
Most Recent Flipbooks
In a recent webinar, Steven Beales, Senior VP, Scientific and Regulatory at WCG, facilitated a conversation with FDA leaders, discussing overreporting SUSARs and the impact on patient safety.
16 industry experts share shifts and trends that will inform clinical research in 2020 and beyond.